Actively Recruiting

Age: 18Years +
All Genders
NCT05417737

Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025

Led by Bernardino Clavo, MD, PhD · Updated on 2025-09-02

105

Participants Needed

1

Research Sites

210 weeks

Total Duration

On this page

Sponsors

B

Bernardino Clavo, MD, PhD

Lead Sponsor

F

Fundación Canaria Instituto de Investigación Sanitaria de Canarias

Collaborating Sponsor

AI-Summary

What this Trial Is About

The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between June-2022 and December-2025

CONDITIONS

Official Title

Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 18 years old or older
  • Referred to the Chronic Pain Unit for palliative ozone therapy due to lack of effective standard treatment, treatment failure, or high risk/morbidity with standard treatment
  • Potential benefit expected from adding ozone therapy to current treatment
  • No contraindications for ozone therapy
  • Signed informed consent for compassionate ozone treatment and study participation
Not Eligible

You will not qualify if you...

  • Younger than 18 years old
  • Psychiatric illness or social situations limiting study compliance
  • Unable to complete required questionnaires or scales
  • Hemodynamically or clinically unstable or have uncontrolled severe illness
  • Uncontrolled cancer requiring chemotherapy
  • Life expectancy less than 6 months
  • Contraindications or inability to attend scheduled treatments
  • Known allergy to ozone
  • Pregnant at enrollment (for systemic ozone therapy)
  • Hemochromatosis (for systemic ozone therapy)
  • Significant glucose-6-phosphate dehydrogenase deficiency (for systemic ozone therapy)
  • Failure to meet all inclusion criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Dr. Negrín University Hospital

Las Palmas, Las Palmas, Spain, 35019

Actively Recruiting

Loading map...

Research Team

B

Bernardino Clavo, MD, PhyD

CONTACT

F

Francisco Rodríguez-Esparragón, BSci, PhyD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here